Navigation Links
AQUA(R) Technology Recognized as 'Promising New Strategy' for Hormone Receptor Testing in Breast Cancer by NCCN Task Force
Date:11/17/2009

NEW HAVEN, Conn., Nov. 17 /PRNewswire/ -- HistoRx today announced that the Company's proprietary AQUA technology, an automated image analysis platform based on tissue-based quantitative immunofluorescence, was noted in a recent National Comprehensive Cancer Network (NCCN) Task Force Report on hormone receptor testing in breast cancer as one of the "... promising new strategies being developed for the measurement of ER and PgR in breast cancer tissue." Experts from the country's leading cancer treatment institutions responded in the report to growing concerns about hormone receptor testing in breast cancer by standard immunohistochemistry (IHC) methodology, particularly a high false-negative rate, and clarified how such testing can be improved. Hormone receptor testing, which includes estrogen receptor (ER) and progesterone receptor (PgR), is a standard part of the diagnostic characterization of an individual's breast cancer and drives treatment decision making.

"The NCCN Task Force Report demonstrates the growing confidence within oncology circles that AQUA analysis provides a new and promising approach to hormone receptor testing," said Rana K. Gupta, CEO of HistoRx. "We believe the upcoming ASCO-CAP guidelines will reinforce the Task Force's assessment that current methods of ER testing are flawed and will further underscore the need for a better solution. AQUA technology's sensitivity, reproducibility and quantification improve upon standard immunohistochemistry testing and can play an important role in improving the overall accuracy of hormone receptor testing."

An early example of personalized medicine, ER testing and PgR testing are typically performed by standard IHC. AQUA® technology brings standardization and reproducibility to IHC analysis and is the only platform capable of precisely measuring protein biomarker concentration with subcellular resolution in tissue sections. This advance enables fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making. AQUA's proprietary software uses automated fluorescent image acquisition and data analysis to provide precise quantification of protein biomarkers of interest, including hormone receptors. HistoRx has developed ER and PgR tests based on AQUA® technology. Both of these assays have been used to analyze the TEAM trial, a randomized, international study of more than 9,000 postmenopausal women with hormone sensitive early breast cancer. Results from this analysis will be discussed at the San Antonio Breast Cancer Symposium in December 2009.

[About HistoRx] HistoRx, Inc. is a leading developer of tissue-based theranostic solutions to advance individualized patient care. The Company's products and services are based on proprietary AQUA® technology for tissue biomarker analysis. AQUA® software is the only platform capable of precisely measuring protein biomarker concentration with subcellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide targeted drug development and therapeutic decision making. HistoRx currently helps biopharmaceutical companies advance their product pipelines by generating valuable new insights into the safety and effectiveness of targeted therapeutics in development for cancer and other diseases, and is developing clinical assays based on these insights.

SOURCE HistoRx, Inc.


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. CLIA Waiver Submitted for Rapid HIV Test Employs StatSures Barrel Technology
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
11. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017 FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s ... where cannabis is legal will generate $655 million in taxes on ... cannabis specific taxes, such as Washington State,s ... earned from state sales taxes that are applied on all retail ...
(Date:3/27/2017)... March 27, 2017 BioLineRx Ltd. (NASDAQ/TASE: ... announced today that AGI-134, an immunotherapy for the treatment of ... Ltd., will be featured at the upcoming American Association ... Washington, DC to be held on April 1-5, ... ...
(Date:3/27/2017)... 2017   Pulmatrix, Inc . (NASDAQ: PULM), a clinical ... pulmonary diseases, today announced that it has added two experts ... asthma to its Scientific Advisory Board . ... B. Moss , MD, former chief of the Pediatric Pulmonary ... Center at Stanford University, and David ...
Breaking Medicine Technology:
(Date:3/27/2017)... Cranbury, NJ (PRWEB) , ... March 27, 2017 ... ... publication of cutting-edge news, research and conference coverage on veterinary medicine, announces the ... The inaugural issue will be packaged with the April edition of American Veterinarian™. ...
(Date:3/27/2017)... Farmingdale, NY (PRWEB) , ... March 27, 2017 ... ... specializing in epigenetic research products enables researchers to pursue the recent RNA methylation ... RNA methylation . In light of the newfound characteristics of N6-methyladenosine, or ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... According to ... prostate cancer, including all stages, is more than 95%. Once the cancer spreads to ... less than 30%. To find out how to avoid this latter group, tune in ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending LLC announced ... litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil No. 1:14-CV-00121-CW/ ... to announce that we have now reached a settlement agreement regarding the ongoing ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading provider of ... latest products to the Deaf Seniors of America Conference, April 4-7 at the Hotel ... with knowledgeable ASL friendly staff from Harris Communications and to try out the newest ...
Breaking Medicine News(10 mins):